Additionally, recent evidence further suggested that short-term administration of emodin (40 mg/kg) for 10 days before mastectomy surgery effectively suppressed EMT and cancer stem cell formation, and thus harbored the potential to halt metastatic recurrence of breast cancer, via blocking TGF-β1-mediated crosstalk between tumor-associated macrophages and cancer cells [137]. The gene discussed is TGFB1; the disease is cancer.